Abstract

AGO2 (Argonaute 2, EIF2C2) is the only member in AGO family with catalytic activity and of extreme importance during small RNAs guided gene silencing processes. The structural investigations have provided insights into details and functional mechanisms of the four major domains within AGO2. As a multifunction player, AGO2 has been revealed involved in tumorgenesis through miRNAs-dependent or independent ways. And nowadays, AGO2 has also been more importantly found ectopically over-expressed in carcinomas and closely associated with aspects of cancers in means of interacting with well-known tumor factors. Here, we provide a review on structural insights, functional mechanisms, novel roles and relationship with carcinomas of AGO2.

Key words: Argonaute-2, carcinomas, microRNAs, angiogenesis

1. Introduction

AGO2 (Argonaute-2), also termed as EIF2C2, belongs to the Argonaute family which is highly conserved in species and symbolized by PIWI domain and crescent PAZ domain [1]. Human Argonaute family can be divided into two subfamilies: one is AGO subfamily, including AGO1, AGO2, AGO3, AGO4, and similar with Arabidopsis thaliana AGO1; the other is PIWI subfamily, including HIWI1, HIWI2, HIWI3, HIWI4, and similar with Drosophila PIWI. PIWI subfamily proteins are exclusively expressed in germ-line cells, but AGO subfamily proteins are broadly expressed in most tissues [2, 3].

In human AGO family, AGO2 has been revealed as the only member with catalytic activity and essential role within RISC complex, so to regulate small RNAs guided gene silencing processes [1]. Notably, different from other members of AGO family including AGO1, AGO3 and AGO4, AGO2 has also been proved indispensable in murine embryonic development by the finding that knock-out Ago2 gene was lethal [4, 5]. In 2012, the crystal structure of human AGO2 combined with pre-miRNAs was revealed, and functional details of the four major domains were also clearly clarified, including the N domain which initiates duplex RNAs unwinding during RISC assembly, the PAZ domain which contains a variant OB fold and bind to 3’ overhang of small RNAs, the MID domain which recognizes 5’ nucleotides of the guide RNAs through Rossmann-like fold, and the PIWI domain which endows AGO2 catalytic activity due to its putative slicer catalytic site [1].

2. Structural Information and Functional Molecular Mechanisms of AGO2

2.1 Structural Information

Recent studies on the structure of AGO2 have revealed the four core domains and details of their functions. The four domains array into a bi-lobe format consisting of N-PAZ and MID-PIWI, and connected by Linker 1 (L1) and Linker 2 (L2). The two lobes form a gap which accommodates the guide small RNAs and their complementary fragments in the middle [6]. The details of each core domain will be discussed below and simply showed in figure 1.
Fig 1. Linearized depiction of human AGO2. Four major domains and their core functions are showed.

**N Domain:** During the formation of RISC complex, unwinding of the RNAs, wrapped inside AGO2 is a rate limiting step. In this process, slicer dependent or independent, functional N domain is indispensable. However, N domain is not required for RNA loading or slicing [7]. In *Thermus thermophilus*, N domain has another important role by stopping the base pairing between guide RNAs and target mRNAs right at the 16th base of the guide RNAs [8]. For eukaryotic AGO2, this function of N domain has not been showed.

**PAZ Domain:** PAZ domain exists in both AGO2 and Dicer, and highly conserved in species and characterized by its OB-fold structure which binds to single nucleotide strand through anchoring the 2-nucleotide of 3’ overhang. And this is considered as the main function of PAZ domain in AGO2 [9]. To confirm this, mutant PAZ and its impact on AGO2 were also investigated, and found that AGO2 with mutant PAZ domain could still interact with small RNAs, but was unable to unwind small RNAs or consequently form RISC complex. So PAZ domain/N-PAZ lobe is strictly required for AGO2 to form RISC complex [10, 11].

**MID Domain:** Among PAZ and PIWI domains, MID domain adopts Rossmann-like fold and provides a binding pocket for 5’ overhang of the guide RNAs [12]. Additionally, MID domain has another assistant site close to this binding site to function synergistically. Both sites have the same two sulfate ions and highly conserved Lys 599 and Lys 638, this renders MID domain the affinity toward m7GpppG cap on target mRNAs [13].

**PIWI Domain:** PIWI domain exerts three major functions within AGO2, including enduring RNase H like endonucleolytic activity, containing tryptophan binding area which is critically needed for the enrollment of GW182 and other tryptophan rich factors, regulating the interaction between MID domain and DNA/RNA due to the polarity and hydrophily on the surface of MID-PIWI lobe, for whose stability maintenance, the D603 on PIWI domain is indispensable [14, 15].

### 2.2 Molecular Mechanisms of AGO2 Functions

As a multi-role player, AGO2 plays important role in small RNAs guided gene silencing processes, including RNA interference, translation repression and heterochromatinization. The functional mechanisms are discussed below.

**Degradation of mRNAs:** As a core element of RISC complex, AGO2 could directly initiate the degradation of target mRNAs through its catalytic activity in gene silencing processes guided by siRNAs or miRNAs, and this is also a rate limiting step of RNA interference [16, 17]. So, over expression AGO2 by genetic manipulation might be promising in improving the RNA interference drug efficacy and decreasing side effect due to its ability to enhance RNA interference validity [18].

**Translation Repression:** Researches have already revealed that AGO2 could repress target gene translation in at least four ways: 1) competing with translation initiating factor eIF4E in binding to m7G cap of target mRNAs, so to hinder the assembly of ribosome and translation initiation [19]; 2) blocking the formation of 80s ribosome from 60s and 40s ribosome by recruiting eIF6, then to stop translation initiation [20]; 3) inducing the de-adenylation, uncapping and degradation of target mRNAs by recruiting GW182 through its P470 and P505 sites [21]; 4) combining with other AGO proteins, like AGO1 and/or AGO3, to form PUF/AGO/eEF1A complex, which inhibits the extension of peptides during translation [22].

**Heterochromatinization:** AGO2 is normally located on euchromatin instead of heterochromatin, combining with CTCF/CP190, and then inhibits related target gene expression through CTCF/CP190 dependent Fab-8 insulation. And this regulatory pattern of AGO2 is RNA interference independent [23]. Another study reported that AGO2 could be occasionally located on euchromatin with AGO1 together, and this facilitated spliceosome recruitment and formation, then promoted the H3K9 methylation of specific exons with the assistance from Dicer and HP1r, so to selectively modulate the transcription elongation efficacy of RNA polymerase and improve gene alternative splicing [24].

**Other Mechanisms:** In addition to serve as an executor of target mRNAs degradation or gene silencing guided by miRNAs, AGO2 could also act as an RNA slicer in Dicer independent way, and regulator of miRNAs maturation [25, 26]. Researchers have also found that AGO2 could enhance miRNAs stability. By these two ways, AGO2 improves gene silencing guided by miRNAs [27]. The functional mechanisms of AGO2 will be described in figure 2.
3. AGO2 in Carcinomas

3.1 AGO2 is Over-expressed in Cancers

Data have showed that miRNAs are critical in tumorigenesis. As a key regulator of miRNAs function and maturation, AGO2 has also been found over-expressed in carcinomas, including Colon Cancer [28], Head and Neck Squamous Cell Cancer [29], Urothelial Carcinoma of Bladder [30], Ovarian Carcinoma [31], Gastric Carcinoma [32], and Colorectal Carcinoma [33]. And the over-expression of AGO2 has been proved to be related to aspects of cancers, including tumor cell growth, overall survival of cancer patients [34, 35]. We and others have previously showed that AGO2 was frequently over-expressed in HCC (Hepatocellular Carcinoma) tissues and cell lines, the over-expression of AGO2 facilitated oncogenic miRNAs (like miR-21) to repress targets, but the regulatory capacity of tumor suppressive miRNAs (like let-7) was contrary unaltered [35, 36]. We also creatively found and reported feed-back regulatory loop between AGO2 and miRNAs by revealing that AGO2 could be reciprocally inhibited by miR-99a which was remarkably decreased in HCC tissues. But contradict to the conclusion made by other groups in our previous study we did not found significant impact of knocking down Ago2 on HCC cell propagation in vitro. Whereas, knocking down Ago2 did severely impaired tumor growth of HCC in vivo. The overview of AGO2 in carcinomas is summarized in Table 1.

Table 1. AGO2 in Carcinomas

| Ref. | Carcinomas                          | Total Cases | AGO2 Expression | Positive Cases | Negative Cases |
|------|-------------------------------------|-------------|-----------------|----------------|---------------|
| [28] | Colon Carcinoma                     | 75          | 74 (98.67%)     | 1 (1.33%)      |               |
| [30] | Urothelial Carcinoma of Bladder     | 106         | 96 (90.57%)     | 10 (9.43%)     |               |
| [31] | Ovarian Carcinoma                   | 103         | 103 (100%)      | 0 (0%)         |               |
| [33] | Colorectal Carcinoma                | 76          | 43 (56.6%)      | 33 (43.4%)     |               |
| [37] | Smooth Muscle Carcinoma of Soft Tissues | 110      | 107 (97.3%)     | 3 (2.7%)       |               |
| [38] | Prostate Carcinoma                  | 107         | 61 (57%)        | 46 (43%)       |               |
| [38] | Esophageal Carcinoma                | 58          | 34 (58.4%)      | 24 (41.6%)     |               |
| [34] | Gliomas                             | 129         | 120 (100%)      | 0 (0%)         |               |
| [39] | Myeloma                             | 53          | 53 (100%)       | 0 (0%)         |               |
| [35] | Hepatocellular Carcinoma            | 152         | 105 (69.07%)    | 47 (30.93%)    |               |

However, others reported that in melanoma, AGO2 expression was strongly reduced in protein level, but not mRNA level [40], and over-expression of AGO2 by genetic manipulation could inhibit cell and tumor growth [41, 42]. This contradiction could be explained as: the expression level of AGO2 is likely variable between cancer types, due to their different miRNAs expression patterns [43, 44]. Moreover, AGO2 has been revealed associated with aspects of cancer, including angiogenesis, metastasis and other
processes, and the regulatory mechanisms for these processes are heterogeneous among cancer types and stages [45, 46]. Therefore, miRNAs expression patterns, cancer types, cancer stages and cancer developmental regulation mechanisms are major determinants of AGO2 expression and function. Hence, more elaborated and systematic experimental design will be helpful to exclude variants before conclude the role of AGO2 in a certain type of cancer.

3.2 AGO2 Related Pathways in Carcinomas

As discussed above, miRNAs/oncogenes/tumor suppressive genes are critical in tumorgenesis. As an essential mediator of miRNAs function and maturation, AGO2 could undoubtedly affect tumorgenesis. But recently, AGO2 was also proved function directly without miRNAs participation in cancers by interacting with famous tumor factors. The diagrammatic overview on the role of AGO2 in cancer is described in fig 3.

![Diagram showing AGO2's role in cancer]

3.2.1 AGO2 and AKT3

In 2013, Shane R. Horman and others reported that AKT3 could phosphorylate AGO2 at S387, enhance its binding with GW180 and entry into P-bodies, so to repress expression of target genes. When S387 was not phosphorylated, AGO2 could just function as RNA endonuclease, mediate the degradation of target mRNAs directly. Therefore, AKT3 might be the switch between the two functional patterns of how AGO2 mediates target mRNAs degradation [47].

3.2.2 AGO2 and EGFR

In 2013, Jia Shen and others reported that under hypoxia situation, EGFR was frequently over expressed, this led to the improvement of EGFR mediated propagation pathways as well as EGFR desquamation from membranes, desquamated EGFR would be captured by vesicles and transferred into cells. Those transferred EGFR molecules could phosphorylate AGO2 at Tyr393, and thus attenuate its affinity toward Dicer and impede the maturation of long-loop miRNAs. Interestingly, most long-loop miRNAs were tumor suppressive. So they concluded that, hypoxia situation which occurs frequently in solid tumors, hindered the maturation of tumor suppressive miRNAs through AGO2/EGFR, and consequently promoted the survival and metastasis of tumor cells. They also confirmed this by clinical investigation on the association between AGO2 expression and breast cancer patients’ overall survival. Results showed consistence [48, 49].

3.2.4 AGO2 and P4H

P4H (Prolyl-4-hydroxylase), which is inhibited under hypoxia situation, was reported as a master of hypoxia response by controlling the stability of HIF [50]. In 2008, Hank H. Qi and others reported the physical interaction between AGO2 and P4H subunits α-(P4H-α(I)) and β-(P4H-β). By mass spectrometric analysis, they identified that the endogenous AGO2 could be hydroxylated at proline 700 and enhanced by P4H subunits. Mutation at proline 700 or dysfunction of P4H subunits resulted in decreased stability of AGO2 [51].

Moreover, AGO2 was also found to regulate FGF2 expression and miRNAs stability. By binding to miRNAs, AGO2 could prolong their half-time, especially for extracellular miRNAs [52]. In 2013, Benoit Laffont and others revealed the mechanism of how AGO2 prolonged miRNAs half-time, that is, the complex of miRNAs/AGO2 could be effectively wrapped by platelet derived micro-particles and transferred into vascular endothelial cells, then affected related signaling pathway inside [53].

3.3 AGO2 and Cancer Angiogenesis

Many researches on the mechanism of angiogenesis have revealed that angiogenesis is a complicated process, and intricately regulated by factors including VEGF, PDGF, FGF, TGF, MMP, Angiopoietin, Angiostatin, Endostatin and so on [54]. As essential regulator of gene expression, miRNAs function and executor—DICER has been indicated playing...
important role in tumor angiogenesis [55]. How is AGO2 in angiogenesis?

In 2008, Tomohiro Asai and others proved that AGO2 could directly regulate the angiogenesis of vascular endothelial cells. They also showed that knock-down of Ago2 in HUVECs (human umbilical vein endothelial cells), which are strictly required in vascularization, induced apoptosis and disabled vessel formation [56]. In our previous study, we found that knock-down of Ago2 by siRNAs significantly impaired HCC growth in vivo instead of in vitro. We also astonishingly noticed that the severely attenuated HCC angiogenesis might be a cause for this [35]. By examining the expression of angiogenesis related factors, we found the correlation between AGO2 and VEGF in HCC cell lines. This was confirmed by the reduction of VEGF in vitro and in vivo when we knock-down Ago2. Through further investigations over the underlying mechanisms, we revealed that PTEN was a mediator of the interaction between AGO2 and VEGF (In Press). So AGO2 is probably a potential target for treatment of carcinomas, and it is of great interests to further investigate the relationship and the underlying mechanisms of AGO2 with angiogenesis in other carcinomas.

In addition to be associated with aspects of tumorgenesis, AGO2 has also been related to be related to stem cell pluripotency maintenance [57], cell differentiation [58], pancreatic β cell expansion [42], skeletal muscle homeostasis modulation [59], microvesicles function [60] and hypoxic adaptation [61]. All these newly found roles of AGO2 are enlightening and refreshing our understanding of AGO2 in carcinogenesis, but further studies are needed.

Conclusion

Being an important miRNAs machinery, AGO2 has been found involving in tumorgenesis in a miRNAs-dependent manner. Recently, the alternative role of AGO2 has also been concerned to directly regulate tumorgenesis through interacting with other tumor-associated factors. Although the identified functions of AGO2 across different types of cancer are contradicted, emerging data have undoubtedly showed that AGO2 implicated in the regulation of many biological processes of cancer, including proliferation, metastasis, angiogenesis and et al. Furthermore, the versatile roles of AGO2 found in normal cells, especial regulation of cell differentiation fate, have broadened potential function of AGO2 in tumorgenesis. In summary, these related works mentioned above have made AGO2 served as a hot target in cancer research.

Acknowledgments

This work was supported by National Science Funds for general project (No. 8100103) and Creative Research Groups (No. 81221061), Chinese Key Project for Infectious Diseases (No. 2012ZX0002-014-005, 2013ZX10002-010-007), Military Youth Project ( No. 13QNP101 ) and State Project For Essential Drug Research and Development (2013ZX09102-060).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Hock J, Meister G: The Argonaute protein family. Genome biology 2008, 9(2):210.
2. Meister G: Argonaute proteins: functional insights and emerging roles. Nature genetics 2013, 45(7):447-459.
3. Schirle NT, MacRae II: The crystal structure of human Argonaute2. Science 2012, 336(6084):1037-1040.
4. Morita S, Horii T, Kimura M, Goto Y, Ochiya T, Hatada I: One Argonaute family member, Eit2a (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics 2007, 89(6):687-696.
5. Shekar PC, Naim A, Sarathi DP, Kumar S: Argonaute-2 null embryonic stem cells are retarded in self-renewal and differentiation. Journal of biosciences 2011, 36(4):649-657.
6. Kuhn CD, Joshua-Tor L: Eukaryotic Argonautes come into focus. Trends in biochemical sciences 2013, 38(5):263-271.
7. Kwak PB, Tomari Y: The N domain of Argonaute drives duplex unwinding during RBSC assembly. Nature structural & molecular biology 2012, 19(2):145-151.
8. Wang Y, Juranek S, Li H, Sheng G, Wardle GS, Tuschl T, Patel DJ: Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature 2009, 461(7265):754-761.
9. Ma JB, Ye K, Patel DJ: Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 2004, 429(6989):318-322.
10. Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, Martienssen RA, Hannon GJ, Joshua-Tor L: The crystal structure of the Argonaute2 PAZ domain reveals a RNA binding motif in RNAi effector complexes. Nature structural biology 2003, 10(12):1026-1032.
11. Gu S, Jin L, Huang Y, Zhang F, Kay MA: Slicing-independent RISC activation requires the argonaute PAZ domain. Current biology : CB 2012, 22(16):1536-1542.
12. Boland A, Hunzinger E, Schmidt S, Iazurradle E, Weichenrieder O: Crystal structure of the MID-PIWI lobe of a eukaryotic Argonaute protein. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(26):10466-10471.
13. Boland A, Tritschler F, Heimstadt S, Iazurradle E, Weichenrieder O: Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein. EMBO reports 2010, 11(7):522-527.
14. Parker JS, Roe SM, Barford D: Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 2005, 434(7033):663-666.
15. Girard A, Sachidanandam R, Hannon GJ, Carmell MA: A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006, 442(7109):199-202.
16. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschi T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular cell 2004, 15(2):185-197.
17. Chang J, Cho H, Lee HC, Kim YK: microRNA/Argonaute 2 regulates nonsense-mediated messenger RNA decay. EMBO reports 2010, 11(5):380-386.
18. Borner K, Nioppek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Pasquinelli AE, Shiekhattar R: MicroRNA silencing through RISC recruitment of Ago2 represses translation. Cell 2007, 129(6):1141-1151.
19. Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT, Mourelatos Z: An RNA m7G cap binding-like motif within human Ago2 vectors and cell lines. Nucleic acids research 2013, 41(21):e199.
20. Girard A, Sachidanandam R, Hannon GJ, Carmell MA: A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006, 442(7109):199-202.
21. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschi T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular cell 2004, 15(2):185-197.
22. Chang J, Cho H, Lee HC, Kim YK: microRNA/Argonaute 2 regulates nonsense-mediated messenger RNA decay. EMBO reports 2010, 11(5):380-386.
23. Borner K, Nioppek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Zhang X, Schurma nn N, Mockenhaupt S, Serva A et al: Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic acids research 2013, 41(21):e199.
24. Girard A, Sachidanandam R, Hannon GJ, Carmell MA: A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006, 442(7109):199-202.
25. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschi T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular cell 2004, 15(2):185-197.
26. Chang J, Cho H, Lee HC, Kim YK: microRNA/Argonaute 2 regulates nonsense-mediated messenger RNA decay. EMBO reports 2010, 11(5):380-386.
27. Borner K, Nioppek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Zhang X, Schurmann N, Mockenhaupt S, Serva A et al: Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic acids research 2013, 41(21):e199.
23. Moshkovitch N, Nisha P, Boyle PJ, Thompson BA, Dale RK, Lei EP: RNAi-independent role for Argonaute2 in CTGF/PI3K99aomatulin inhibitor function. *Genes & development* 2011, 25(16):1686-1701.

24. Ameyar-Zazoua M, Rachez C, Soudal O, Robin P, Fritsch L, Young R, Morozova N, Fenui R, Descotes N, Andrau JC et al: Argonaute proteins couple chromatin silencing to alternative splicing. *Nature structural & molecular biology* 2012, 19(10):998-1004.

25. Cheloufi S, Dos Santos GC, Chong MM, Hannon GJ: A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. *Nature* 2010, 465(7304):584-589.

26. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Han J, Lawson ND et al: A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. *Science* 2010, 328(5986):1694-1698.

27. Winter J, Diederichs S: Argonaute proteins regulate microRNA stability: Increased microRNA abundance by Argonaute proteins is due to microRNA stabilization. *RNA biology* 2011, 8(6):1149-1157.

28. Li L, Yu C, Gao H, Li Y: Argonaute proteins: potential biomarkers for human colon cancer. *BMC cancer* 2010, 10:83.

29. Chang SS, Smith I, Glazer C, Hennessey P, Califano JA: EIF2C is upregulated and amplified in head and neck squamous cell carcinoma. *ORL: journal for oro-rhino-laryngology and its related specialties* 2010, 72(6):337-343.

30. Yang FQ, Huang JH, Liu M, Yang F, Li W, Wang GC, Che JP, Zheng JH: Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. *International journal of clinical and experimental pathology* 2014, 7(1):340-347.

31. Vaksmann O, Hietland TE, Trope CG, Reich R, Davidson B: Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. *Human pathology* 2012, 43(11):2062-2069.

32. Zhang J, Fan XS, Wang CX, Liu B, Li Q, Zhou XJ: Up-regulation of Ago2 expression in gastric carcinoma. *Med Oncol* 2013, 30(3):628.

33. Papachristou DJ, Korpetinou A, Giannopoulou E, Antonopoulou AG, Papadaki H, Grivas P, Scopa CD, Kalofonos HP: Expression of the ribonucleases Drosa, Dicer, and Ago2 in colorectal carcinomas. *Viruses: Arkiv f?r en internationell journal of molecular medicine* 2011, 4(3):431-440.

34. Feng B, Hu P, Lu SJ, Chen JY, Ge RL: Increased argonaute 2 expression in gliomas and its association with tumor progression and poor prognosis. *Asian Pacific journal of cancer prevention* 2014, 15(9):4079-4083.

35. Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Ding M, Yang Y, Li L, Fu S et al: miRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. *Oncogene* 2014, 33:e97.

36. Cheng N, Li Y, Han ZG: Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma. *Hepatology* 2013, 57(3):1906-1918.

37. Papachristou DJ, Sklouros E, Corradi D, Grassani C, Kontogeorgakos V, Rao UN: Immunohistochemical analysis of the endoribonucleases Drosa, Dicer and Ago2 in smooth muscle tumours of soft tissues. *Histopathology* 2012, 60(6):E28-36.

38. Yoo NJ, Hur SY, Kim MS, Lee JY, Lee SH: Immunohistochemical analysis of RNA-induced silencing complex-related proteins AGO2 and Dicer2 in prostate and esophageal cancers. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica* 2010, 118(4):271-276.

39. Wu S, Yu W, Qu X, Wang R, Xu J, Zhang Q, Li J, Chen L: Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. *Journal of hematology & oncology* 2014, 7(1):40.

40. Voller D, Reinders J, Meister G, Rosserhoff AK: Strong reduction of AGO2 expression in melanoma and cellular consequences. *British journal of cancer* 2013, 109(12):3116-3124.

41. Zhang X, Graves P, Zeng Y: Overexpression of human Argonaute2 inhibits cell and tumor growth. *Biochimica et biophysica acta* 2013, 1830(3):2553-2561.

42. Tattikota SG, Rathjen T, McAnulty SJ, Wessels HH, Akerman I, van de Bunt M, Haussser J, Enguerra JL, Masini M, Pesando JM et al: Argonaute2 mediates compensatory expansion of the pancreatic beta cell. *Cell metabolism* 2014, 19(1):122-134.

43. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. *Trends in molecular medicine* 2014, 20(8):460-469.

44. Li Z, Rana TM: Therapeutic targeting of microRNAs: current status and future challenges. *Nature reviews Drug discovery* 2014, 13(9):622-638.

45. Meacham CE, Morrison SJ: Tumour heterogeneity and cancer cell plasticity. *Nature* 2013, 501(7467):328-337.

46. Juntila MR, de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature 2013, 501(7467):346-354.

47. Horman SR, Janas MM, Litterst C, Wang B, MacRae IJ, Sever MJ, Morrissey DV, Graves P, Luo B, Umesalma S et al: A-ki-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. *Molecular cell* 2013, 50(3):356-367.

48. Shen J, Xia W, Khokharya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH et al: EGFR modulates miRNA maturation in response to hypoxia through phosphorylation of AGO2. *Nature* 2013, 497(7449):383-387.

49. Hauptmann J, Meister G: Argonaute regulation: two roads to the same destination. *Developmental cell* 2013, 25(6):553-554.

50. Miolyharju J: Prolyl 4-hydroxylase, master regulators of the hypoxia response. *Acta Physiol (Oxf)* 2013, 208(2):148-165.